T Mixcoatl-Zecuatl1, C G Jolivalt. 1. Department of Pathology, University of California, San Diego, La Jolla, CA 92093-0612, USA.
Abstract
BACKGROUND AND PURPOSE: This study was designed to clarify mechanisms responsible for the anti-allodynic effects of duloxetine in diabetes. EXPERIMENTAL APPROACH: The streptozotocin-induced diabetic rat model was used to compare the efficacy of duloxetine, 5-HT, the 5-HT(2A) receptor agonist [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI)] and two antagonists (ketanserin and pruvanserin) on tactile allodynia. KEY RESULTS: Systemic or intrathecal injection of duloxetine alleviated tactile allodynia in diabetic rats. The effect of systemic duloxetine was reduced by intrathecal administration of ketanserin or pruvanserin, indicating participation of spinal 5-HT(2A) receptors in the mechanism of action of duloxetine. In contrast to spinal delivery, systemic and local peripheral injections of ketanserin or pruvanserin alleviated tactile allodynia in diabetic rats. This effect was reversed immediately after systemic or local DOI injection. CONCLUSIONS AND IMPLICATIONS: These results support the involvement of spinal 5-HT(2A) receptors in the ability of duloxetine to ameliorate painful diabetic neuropathy. Our data also suggest that the role of 5-HT(2A) receptors depends on the level of the neuraxis at which activation takes place, with peripheral activation contributing to tactile allodynia in diabetic rats, whereas spinal activation of this receptor alleviates tactile allodynia. The development of selective peripheral 5-HT(2A) receptor antagonists may offer a novel approach for the treatment of diabetic neuropathic pain.
BACKGROUND AND PURPOSE: This study was designed to clarify mechanisms responsible for the anti-allodynic effects of duloxetine in diabetes. EXPERIMENTAL APPROACH: The streptozotocin-induced diabeticrat model was used to compare the efficacy of duloxetine, 5-HT, the 5-HT(2A) receptor agonist [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI)] and two antagonists (ketanserin and pruvanserin) on tactile allodynia. KEY RESULTS: Systemic or intrathecal injection of duloxetine alleviated tactile allodynia in diabeticrats. The effect of systemic duloxetine was reduced by intrathecal administration of ketanserin or pruvanserin, indicating participation of spinal 5-HT(2A) receptors in the mechanism of action of duloxetine. In contrast to spinal delivery, systemic and local peripheral injections of ketanserin or pruvanserin alleviated tactile allodynia in diabeticrats. This effect was reversed immediately after systemic or local DOI injection. CONCLUSIONS AND IMPLICATIONS: These results support the involvement of spinal 5-HT(2A) receptors in the ability of duloxetine to ameliorate painful diabetic neuropathy. Our data also suggest that the role of 5-HT(2A) receptors depends on the level of the neuraxis at which activation takes place, with peripheral activation contributing to tactile allodynia in diabeticrats, whereas spinal activation of this receptor alleviates tactile allodynia. The development of selective peripheral 5-HT(2A) receptor antagonists may offer a novel approach for the treatment of diabetic neuropathic pain.
Authors: Gerd D Bartoszyk; Christoph van Amsterdam; Henning Böttcher; Christoph A Seyfried Journal: Eur J Pharmacol Date: 2003-07-25 Impact factor: 4.432
Authors: F P Bymaster; L J Dreshfield-Ahmad; P G Threlkeld; J L Shaw; L Thompson; D L Nelson; S K Hemrick-Luecke; D T Wong Journal: Neuropsychopharmacology Date: 2001-12 Impact factor: 7.853
Authors: Guido M Gaietta; Elizabeth J Yoder; Tom Deerinck; Karen Kinder; Abraham Hanono; Areum Han; Chun Wu; Mark H Ellisman Journal: J Neurocytol Date: 2003-05
Authors: Susanne Koch; Susan K Hemrick-Luecke; Linda K Thompson; David C Evans; Penny G Threlkeld; David L Nelson; Kenneth W Perry; Frank P Bymaster Journal: Neuropharmacology Date: 2003-12 Impact factor: 5.250
Authors: Zeyad Schwen; Yosuke Matsuta; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai Journal: Am J Physiol Renal Physiol Date: 2013-10-23
Authors: Andrew G Marshall; Corinne Lee-Kubli; Shazli Azmi; Michael Zhang; Maryam Ferdousi; Teresa Mixcoatl-Zecuatl; Ioannis N Petropoulos; Georgios Ponirakis; Mark S Fineman; Hassan Fadavi; Katie Frizzi; Mitra Tavakoli; Maria Jeziorska; Corinne G Jolivalt; Andrew J M Boulton; Nathan Efron; Nigel A Calcutt; Rayaz A Malik Journal: Diabetes Date: 2017-02-15 Impact factor: 9.461